Page last updated: 2024-12-11
albaconol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
albaconol: from the mushroom Albatrellus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5317148 |
| CHEMBL ID | 512488 |
| MeSH ID | M0456487 |
Synonyms (4)
| Synonym |
|---|
| albaconol |
| bdbm50260043 |
| CHEMBL512488 , |
| 2-[[(1r,2r,4as,8as)-2-hydroxy-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]methyl]-5-methylbenzene-1,3-diol |
Research Excerpts
Overview
Albaconol is a new kind of prenylated resorcinols isolated from the fruiting bodies of the inedible mushroom Albatrellus confluens. Albaconol has been shown to inhibit tumor cell growth.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Albaconol is a new kind of prenylated resorcinols isolated from the fruiting bodies of the inedible mushroom Albatrellus confluens, and has been shown to inhibit tumor cell growth." | ( Plant-derived small molecule albaconol suppresses LPS-triggered proinflammatory cytokine production and antigen presentation of dendritic cells by impairing NF-kappaB activation. An, H; Cao, X; Liu, J; Liu, Q; Shu, X; Sun, A; Sun, Q; Zhang, C, 2008) | 1.36 |
| "Albaconol is a new kind of small compound, prenylated resorcinol, isolated from the fruiting bodies of the inedible mushroom Albatrellus confluens." | ( Albaconol, a plant-derived small molecule, inhibits macrophage function by suppressing NF-kappaB activation and enhancing SOCS1 expression. Cao, X; Liu, J; Liu, Q; Shu, X; Sun, A; Wang, L, 2008) | 2.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | IC50 (µMol) | 5.0000 | 0.0002 | 0.6060 | 10.0000 | AID399920 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (37)
Molecular Functions (15)
Ceullar Components (6)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) |
| external side of plasma membrane | Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) |
| membrane | Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) |
| dendritic spine membrane | Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) |
| neuronal cell body | Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) |
| postsynaptic membrane | Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) |
| plasma membrane | Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (10)
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.41
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||